Kymera Therapeutics Inc.

AI Score

0

Unlock

38.75
0.22 (0.57%)
At close: Feb 06, 2025, 2:53 PM
undefined%
Bid 38.75
Market Cap 2.51B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.34
PE Ratio (ttm) -16.56
Forward PE n/a
Analyst Buy
Ask 38.87
Volume 340,072
Avg. Volume (20D) 479,030
Open 38.50
Previous Close 38.53
Day's Range 38.12 - 39.56
52-Week Range 29.24 - 53.27
Beta undefined

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 184
Stock Exchange NASDAQ
Ticker Symbol KYMR

Analyst Forecast

According to 15 analyst ratings, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56, which is an increase of 44.52% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Kymera Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+7.61%
Kymera Therapeutics shares are trading higher. Ste... Unlock content with Pro Subscription
3 weeks ago
+7.79%
Kymera Therapeutics shares are trading higher after the company announced it's targeting 2025 milestones with its STAT6 and TYK2 oral degraded programs for immunology.